FDA
-
-
-
-
-
-
-
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
-
-
-
-
-
-
-
Cue Biopharma implements 1-for-30 reverse stock split
-
-
-
-
-
-
-
Cue Biopharma Announces CEO Transition
-
-
-
-
-
-
-
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Cue Biopharma reports additional response in head and neck cancer trial
-
-
-
-
-
-
-
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
-
-
-
-
-
-
-
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

